Utilization of prostate-specific membrane antigen positron emission tomography in Australia following government subsidization: Trends in primary staging and biochemical recurrence.
1/5 보강
[BACKGROUND] Prostate-specific membrane antigen positron emission tomography (PSMA-PET) offers superior accuracy over conventional imaging for the primary staging of intermediate- to high-risk prostat
APA
Sandhu K, Lim S, et al. (2026). Utilization of prostate-specific membrane antigen positron emission tomography in Australia following government subsidization: Trends in primary staging and biochemical recurrence.. Prostate international, 14(1), 48-53. https://doi.org/10.1016/j.prnil.2025.09.006
MLA
Sandhu K, et al.. "Utilization of prostate-specific membrane antigen positron emission tomography in Australia following government subsidization: Trends in primary staging and biochemical recurrence.." Prostate international, vol. 14, no. 1, 2026, pp. 48-53.
PMID
41908240 ↗
Abstract 한글 요약
[BACKGROUND] Prostate-specific membrane antigen positron emission tomography (PSMA-PET) offers superior accuracy over conventional imaging for the primary staging of intermediate- to high-risk prostate cancer and in the biochemical recurrence (BCR) setting. In 2022, PSMA-PET became eligible for subsidy under Australia's Medicare Benefits Schedule (MBS), reducing financial constraints and improving access for patients. This study presents the first national analysis of PSMA-PET uptake in Australia since MBS subsidization.
[MATERIALS AND METHODS] This was a retrospective population-based analysis of PSMA-PET studies performed between July 2022 and March 2025 using MBS codes 61563 (primary staging) and 61564 (BCR). Data were stratified by year, state, age group, and setting and standardized per 100000 men using population data.
[RESULTS] A total of 90,412 PSMA-PET imaging studies were performed during the study period, with 60,995 for primary staging and 29,417 for BCR. There was a significant increase for primary staging with an average rise of 1.56 studies per 100000 men ( = 0.04; 95% confidence interval: 0.07-2.99). New South Wales recorded rapid and sustained growth, while Queensland maintained the highest per capita usage. Uptake for BCR rose modestly with similar geographic heterogeneity observed ( = 0.28; 95% confidence interval = 0.37-1.23).
[CONCLUSIONS] Our findings demonstrate rapid and widespread uptake of PSMA-PET in Australia following MBS subsidization, especially in primary staging. Regional disparities in access persist, particularly in Western Australia and the Northern Territory. These findings highlight the impact of national health policy on imaging utilization to improve diagnostic staging, and detection of recurrence in prostate cancer, and emphasize the need to address geographic inequities in advancing diagnostic care.
[MATERIALS AND METHODS] This was a retrospective population-based analysis of PSMA-PET studies performed between July 2022 and March 2025 using MBS codes 61563 (primary staging) and 61564 (BCR). Data were stratified by year, state, age group, and setting and standardized per 100000 men using population data.
[RESULTS] A total of 90,412 PSMA-PET imaging studies were performed during the study period, with 60,995 for primary staging and 29,417 for BCR. There was a significant increase for primary staging with an average rise of 1.56 studies per 100000 men ( = 0.04; 95% confidence interval: 0.07-2.99). New South Wales recorded rapid and sustained growth, while Queensland maintained the highest per capita usage. Uptake for BCR rose modestly with similar geographic heterogeneity observed ( = 0.28; 95% confidence interval = 0.37-1.23).
[CONCLUSIONS] Our findings demonstrate rapid and widespread uptake of PSMA-PET in Australia following MBS subsidization, especially in primary staging. Regional disparities in access persist, particularly in Western Australia and the Northern Territory. These findings highlight the impact of national health policy on imaging utilization to improve diagnostic staging, and detection of recurrence in prostate cancer, and emphasize the need to address geographic inequities in advancing diagnostic care.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Long-term trends in androgen-directed therapy in advanced prostate cancer: a 29-year national analysis.
- A structure-based virtual screening approach to identify novel anaplastic lymphoma kinase inhibitors.
- Emerging radiotracers in prostate cancer: opportunities and challenges.
- The Impact of Endpoint Definitions on Predictors of Progression in Active Surveillance for Early Prostate Cancer.
- PSMA Theranostics in Prostate Cancer and Beyond: Current and Future Perspectives.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Prostate Cancer Care for Men with an Intellectual Disability: A Population-based Cohort Study of Symptoms, Diagnosis, Treatment, and Survival.
- Association between polygenic risk scores and cardiovascular events in prostate cancer patients receiving androgen deprivation therapy in Han Chinese.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Interleukin-11: A pivotal player and potential therapeutic target in prostate cancer.
- DIAPH3 is a multifaceted prognostic biomarker that links immunotherapy response to tumor microenvironment in prostate cancer.
- Machine learning approaches to optimize the integration of sociodemographic factors for predicting cancer-specific survival among patients with high-risk prostate cancer.